Background and Summary
======================

Poliovirus (PV), a non-enveloped human enterovirus virus of the Picornaviridae family is the etiological agent of poliomyelitis (polio). Poliovirus symptoms include fever, fatigue, headache, limb pain and permanent paralysis in some cases. Global vaccination campaigns utilizing live-attenuated oral polio vaccines have reduced PV in all but three countries (Afghanistan, Nigeria and Pakistan) which still remain PV-endemic. The global use of live-attenuated vaccines has an increased risk of reversion to wild type and shedding by immune-deficient individuals^[@b1],[@b2]^. Though vaccination is effective, treatment of polio is symptomatic. Enterovirus 71 (EV71), a relative of PV, is a major public health burden in the Western Pacific region associated with severe neurologic symptoms of hand, foot and mouth disease (HFMD), a disease most often contracted by children\<5 years old^[@b3]^. More than 7 million cases of HFMD were reported in mainland China from 2008--2012. EV71 vaccination programs are challenged by high cost and vaccine availability^[@b4]^. Understanding host gene networks that regulate PV and/or EV71 replication, and development of agents against these targets is a promising strategy to prevent and treat PV while eliminating the issues of reversion and shedding.

RNA interference (RNAi) is an evolutionarily conserved pathway of post transcriptional gene regulation involving small double-stranded non-coding RNAs, microRNAs (miRNAs). The 'guide' strand contains a 6 nt 'seed' region that binds complementary miRNA recognition elements (MRE) within the 3′ untranslated regions (3′-UTR) of transcripts in a RNA induced silencing complex (RISC) causing degradation of transcripts or blocking gene translation^[@b5],[@b6]^. PV and EV71 can modulate multiple host pathways including RNAi for their own replication^[@b7]^. The role of miRNAs in these processes is incompletely understood. To understand the role of miRNAs in viral replication, we undertook a high-throughput screen utilizing miRNA inhibitors and mimics to determine which miRNAs alter the replication of poliovirus and the related EV71.

HEp-2C cells were reverse-transfected with non-targeting siRNA, miRNA negative controls, or gene specific mimics for 48 h. The gene specific mimics corresponded to 1,208 known miRNAs in the human genome. Cytotoxicity was evaluated via CytoTox-Glo assay (Promega). Mimics which were not cytotoxic were evaluated. Transfected cells were either mock infected (no virus) or infected with Sabin-2 strains of PV (MOI 0.01) or EV71 (MOI 0.01). EV71 was examined in miRNA-transfected cells, but was not used as part of the entire library screen.

We investigated whether miRNA-transfection with miR-134 inhibited EV71 replication. Mimics/inhibitors against the *C. elegans* miR-67 were used as non-targeting controls while siRNAs targeting the PV capsid (siPol) were used as positive control. Twenty-four hours post-infection, cells were stored at −80 °C. miRNA effects on Sabin-2 replication were evaluated by a PV type-II specific ELISA^[@b14],[@b15]^. Absorbance values were normalized to non-targeting miRNA mimic controls and converted to a z-score. Mimics that resulted in a z-score≤−1.5 s.d. were deemed hits and subjected to validation experiments which utilized miRNA inhibitors targeting the same genes ([Table 1](#t1){ref-type="table"}). Several miRNAs suppressed PV replication. MiR-134 and miR-138 had the most potent antiviral effect against PV Sabin-2 following transfection ([Fig. 1](#f1){ref-type="fig"}). For this reason, the antiviral effects of miR-134 were evaluated further and the resulting data is outlined here. MiR-138 is currently still under evaluation. Ingenuity pathway analysis (IPA; QIAGEN) was utilized to evaluate protein networks associated with PV replication to predict targets of miR-134 that may be involved in PV replication. TargetScan analysis was used to predict target transcripts via seed region complementarity. IPA and TargetScan analysis revealed many predicted targets, of interest was the nuclear transport system protein (RAN) because it miR-197 inhibited EV72 replication^[@b16]^. We confirmed by qPCR of RAN mRNA and miR-134 transcript levels following miR-mimic transfection ([Fig. 2](#f2){ref-type="fig"}). To confirm RAN's role in PV replication, RAN was silenced via siRNA i prior to infection with Sabin-2 PV. Silencing inhibited PV replication in both cell lines ([Fig. 3](#f3){ref-type="fig"}). miR-134 also drastically reduced EV71 replication ([Fig. 4](#f4){ref-type="fig"}). It is also possible that miR-134 may regulate other host genes required for PV replication, which is supported by the evidence that one miRNA can regulate large numbers of target mRNAs^[@b17]^. Hits from primary screen were validated using miRNA specific inhibitors. These findings demonstrate miRNA regulation of PV and EV71 and may provide a novel approach in combating infection.

Methods
=======

Cell culture and viruses
------------------------

HEp-2 is an adherent human epidermoid carcinoma cell line that support PV replication. Caco-2 cells, a colorectal adenocarcinoma (HTB-37) adherent epithelial cell line derived from human colon tissue, were used in conjunction with HEp-2 cells to evaluate the antiviral effects of miR-134 against PV replication. Effects of target gene silencing on poliovirus replication can be detected 24--48 h post-infection (pi), and were utilized for the miRNA screen. Human muscle rhabdomyosarcoma (RD) cells are an adherent cell which supports enterovirus 71 (EV 71) replication and are routinely utilized to determine enterovirus titers post-miRNA transfection. All cell lines were cultured under the same conditions. All experiments were completed with cells at the same passage. As part of this study we investigated whether miRNA-transfection with miR-134 also inhibited replication of EV71, a familial relative of PV, in an effort to evaluate whether viruses within the same family exhibiting similar replication pathways would also be affected by miR-134. These experiments utilized the same negative control miRNA and siRNA as the PV evaluation^[@b18]^.

Briefly, cells were cultured in Dulbecco's modified eagle medium (DMEM; Hyclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS) under cell culture conditions (37 °C, 5% CO~2~). Cells were passaged 24 h prior to transfection. Briefly, cell culture media was removed and cells washed with 1X PBS to remove excess media and FBS. Following washing, cells were detached from the culture flask via addition and incubation with 0.05% Trypsin. Cells were incubated with trypsin under cell culture conditions until cells detached from the flask surface. Trypsin was neutralized with equal volumes of cell culture media containing 10% FBS. Trypsonized cells were removed from the cell culture flask and transferred to a 50 ml conical tube. Cell suspension was pelleted via centrifugation (1 min at 1,200×g). Supernatant was discarded and cells were resuspended in cell culture media containing 10% FBS by pipetting. Resuspended cells were then transferred back to the cell culture flask at the appropriate concentration and incubated under cell culture conditions. Master cell stocks were cultivated and stored at −80 °C. Passage numbers were kept consistent throughout all experiments to reduce variability. HEp-2Cand Caco-2 cells were utilized at P164 and P46, respectively.

The Sabin-2 PV vaccine strain was used throughout this study. This strain of PV is propagated in the African Green Monkey Kidney cell line Vero-P, the approved cell line for polio vaccine production. Cell stocks were obtained from the Centers of Disease Control and Prevention (CDC, Atlanta) who in turn obtained stocks from the Serum Institute of India (SI). Vero-P stocks were cultured under cell culture conditions at 37 °C, 5% CO~2~ in Dulbecco's modified Eagle's medium (DMEM; Hyclone, GE Healthcare) supplemented with 10% heat inactivated fetal bovine serum (FBS; Hyclone, GE Healthcare). Master cell stocks were cultivated and stored at −80 °C. Passage number were kept consistent throughout all experiments to reduce variability. Viral stocks were cultivated, viral titers determined by plaque assay and 50% cell culture infectious dose (CCID~50~), aliquoted and stored at −80 °C until use^[@b19]^.

Primary screening and miRNA mimic transfection
----------------------------------------------

The primary miRNA mimic screen included a library of 1,208 miRNA mimics (GE Dharmacon-Thermo Scientific; CS-001010 Human Mimics Lot 10100 and CS-001015 Supplement Human Mimic 16.0 Lot 11144). Screening was completed in triplicate using a 96-well plate format with HEp-2C cells (10^3^ cells per well). HEp-2C cells were reverse transfected to a final mimic concentration of 25 nM. The Dharmacon miRIDIAN microRNA mimic negative control (miR-NTC; CN-001000-01) was used as a negative control and a siRNA targeting the poliovirus capsid-coding region (siPol) (CDC, provided by Dr Steve Oberste) was utilized to monitor silencing effects on poliovirus replication in all assays. A cytoxicity transfection control siRNA (siTOX) (GE Healthcare Dharmacon TOX Transfection Control, Cat. \# D0015000120) was utilized to visually confirm effective productive transfection. Cells successfully transfected with siTOX undergo apoptosis resulting in cell death. Briefly, mimics were incubated at room temperature for 20 min in 0.3% (0.3 ul per well) of DharmaFECT transfection reagent 4 (DF4) (Dharmacon-Thermo Scientific) prepared in serum-free medium (Opti-MEM, Invitrogen Inc.) prior to addition of cells in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% calf serum. Cells were cultured for 48 h at 37 °C, 5% CO~2~. Forty-eight hours post-transfection, media was removed, cells were washed with phosphate buffer saline (PBS; Hyclone, GE Healthcare) and infected with Sabin 2 at an MOI=0.01 Virus was diluted in DMEM containing 2% calf serum and 1% penicillin-streptomycin. Twenty-four hours post-infection, HEp-2C cells were removed from the culture incubator and stored at −80 °C until evaluated.

Validation screening and removal of false positives
---------------------------------------------------

Following the primary miRNA screen, in an effort to reduce false positives relative to transfection variability, individual miRNA inhibitors (GE Dharmacon Thermo-Fisher; IH-001010 Human Inhibitor Lot 09168 and IH-001015 Supplement Human Hairpin Inhibitor Library 16.0) were utilized to validate miRNA hits produced as part of the primary miRNA mimic screen. Hits producing an opposite phenotype as compared to the miRNA mimics screen were taken into future studies. The miRNA mimics are the focus of this study; therefore, the brief screening of the miRNA inhibitors was not included here and only used as a form of phenotype validation. Briefly, individual miRNA inhibitors corresponding to miRNA hits produced as part of the primary mimic screen were reverse-transfected into HEp-2 cells as previously described. At 48 h post-transfection, cells were infected with Sabin-1, Sabin-2 or Sabin-3 strains (MOI=0.01). Cells were incubated and replication assessed as previously stated. Messenger RNA levels for each gene were evaluated following transfection by qPCR.

Validation screens were completed to further confirm the anti-virus effects of the identified miRNA mimics using ELISA assay. For the list of 108 anti-polio miRNA mimics identified from the primary miRNA mimics screening ([Table 1](#t1){ref-type="table"}), we compared the phenotypes with the miRNA inhibitor data. Following miRNA inhibitor experiments, hits that did not result in opposing phenotypes when compared to their mimic counterparts were excluded. The miRNA mimics which lead to cell death were also excluded. We also identified 29 miRNA mimics that when transfected into cells lead to decreased poliovirus replication ([Fig. 5](#f5){ref-type="fig"}). From this data, miRNA-134 was selected for further investigation in this study.

Polio Type II specific antibody-capture ELISA
---------------------------------------------

A PV type-II specific ELISA was used to determine miRNA effects on Sabin-2 replication. Antibody-capture ELISA for detection of poliovirus was described previously^[@b14],[@b15]^. Briefly, 2HB high-binding 96-well plates (NUNC; 1424561-PK) were coated with 50 ul of the PV type II specific monoclonal antibody (HYB294-06, mouse; Thermo Scientific Pierce) diluted in carbonate-bicarbonate buffer (pH 9.6). Plates were incubated for 16 h (overnight) at 4 °C in a moist chamber. Antibody-coated plates were washed with 0.05% phosphate buffered saline with Tween 20 (PBST). Following washing, plates were blocked with 100 μl blocking buffer (1x PBS containing 0.5% Gelatin and 0.25% Tween) for 60 min at 37 °C. Block was removed and plates were washed 4x with PBST. Fifty microliters of cell lysate was transferred from the thawed infected transfection plate to the antibody-coated plates. Inoculated plates were incubated for 60 min at 37 °C in a moist chamber. Subsequently, plates were washed 4x with PBST and 50 ul of HRP-substrate solution (SureBlue TMB) was added and incubated for 15 min at 37 °C. The reaction was halted by the addition of 50 ul H~2~SO~4~ stop solution. Absorbance was evaluated at a wavelength of 450 nm with a plate spectrophotometer (Tecan). Absorbance values were normalized to non-targeting miRNA mimic controls and converted to a z-score. Z-scores were used to determine whether hits are positive according to methods describe previously^[@b20]^. Hits with a z-score≤−1.5 s.d. were subjected to validation experiments in HEp-2C cells.

Poliovirus (PV) and enterovirus 71 (EV71) plaque assays
-------------------------------------------------------

PV and EV71 viral titers were determined post-transfection by either a HEp-2 or RD cell-based plaque assay, respectively^[@b19],[@b21]^. Briefly, 1.2×10^6^ cells were seeded in each well of six well plates and incubated overnight under standard cell culture conditions. The next day culture media was removed and cells were washed with minimal essential medium (MEM; Hyclone, GE Healthcare, USA) supplemented with 2% fetal bovine serum (FBS). Next, samples were serially diluted 10-fold in MEM with 2% FBS and added to washed plates. Plates were incubated at 37 °C, 5% CO~2~ for 1 h. The inoculum was removed and plates were overlaid with 0.9% nutrient agarose gel in MEM supplemented with 2% FBS, followed by incubation in a 37 °C incubator with 5% CO~2~ for 3 days. Agarose overlay was removed and cells fixed with 10% formaldehyde in PBS. Plaques were visualized by staining with crystal violet. Virus titers were expressed as PFU ml^−1^.

RNA isolation and qRT-PCR
-------------------------

Cells were homogenized and total RNA was extracted using RNAzol RT reagent (Molecular Research Center) according to the manufacturer's instruction. The concentration of the purified RNA was determined by NanoDrop spectrophotometer (Thermo Scientific). To examine mature miR-134-5 expression, 300 ng total RNA was reverse-transcribed to cDNA using the miRNA 1st-Strand cDNA synthesis kit (Agilent Technologies) according to the manufacturer's protocol. For the RAN gene, 300 ng total RNA was reverse-transcribed to cDNA using the AffinityScript QPCR cDNA synthesis kit (Agilent Technologies). For the quantification of individual genes, cDNAs were diluted in water and quantified using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technologies) in an Agilent Mx3005P instrument. Primers specific for miR-134-5p (forward, 5′-TGTGACTGGTTGACCA-3′; reverse, universal primer) RAN (forward, 5′-GAAGCTCATTGGAGACCCTAAC-3′; reverse, 5′-CAACCTCTAAGTCGTGCTCATAC-3′) were used. The gene expression levels were normalized to 18s rRNA gene as an internal control.

Ingenuity pathway analysis and TargetScan analysis
--------------------------------------------------

QIAGEN's Ingenuity pathway analysis (IPA; QIAGEN Redwood City; [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)) was utilized to evaluate protein networks associated with PV replication in an effort to predict targets of miR-134 that may be involved in poliovirus infection and replication. TargetScan analysis (Whitehead Institute for Biomedical Research; <http://www.targetscan.org/>) was used to predict target transcripts via seed region complementarity. Pathway analysis and TargetScan analysis revealed many predicted targets, of interest was the nuclear transport system protein (RAN) because it has been previously published that another microRNA, miR-197, inhibited enterovirus 71 replication by targeting the RAN protein^[@b16]^.

Data normalization and statistical analysis
-------------------------------------------

The current screen was examined using Z'-factor (1\>Z'\>0.5: Excellent assay; 0.5\>Z'\>0: acceptable) to evaluate its quality. The majority of our screen fell into a Z' factor (0.5\<Z'\<1.0) which reflects high-quality of the primary screen. Afterwards, the primary screen data was normalized to the entire plate and generated the mean (μ) of the data to zero and the standard deviation (s.d.) to 1. To achieve a high-quality and robust screen, we used siTOX (GE Healthcare Dharmacon TOX™ Transfection Control, Cat. \# D0015000120) to monitor the transfection efficiency; we also used a siRNA targeting poliovirus (CDC, provided by Dr Steve Oberste) to monitor silencing effects on poliovirus replication (see transfection control section). A non-targeting siRNA (GE Healthcare Dharmacon: Cat. \# D-001810-0X) used as a negative control. All experiments were performed in at least two independent replicates with each experiment consisting of duplicates for each miRNA targeting a specific mRNA transcript for the gene of interest. ELISA absorbance values were normalized by correcting the raw data. The mean of the replicates where calculated and standardized using Z-score analysis. The mean of the wells treated with experimental miRNAs for each miRNA were compared to the mean of negative control treated wells. The Z-score was calculated by finding the difference between the normalized score and the mean of the population and dividing this by the standard deviation of the population. Positive hits from the primary screen are scored by Z-score\>1.5 s.d.

All results are presented as means±s.e. Statistical analysis was done using the one-way ANOVA with Turkey's multiple comparison at 95% confidence level. *P*-values\<0.05 were considered statistically significant.

Data Records
============

Data record 1
-------------

The miRNA mimic screen data presented is available at PubChem under *NCBI PubChem BioAssay* AID 1224906 (Data Citation 1). In this RNAi screen, miRNA mimics corresponding to 1,208 known miRNAs in the human genome were screened in HEp-2 cells for their regulatory effects against Sabin-2 poliovirus. One hundred eight miRNAs resulted in a substantial reduction of poliovirus replication relative to non-targeting control (z-scores≤−1.5). Forty-six miRNAs resulted in a substantial increase of poliovirus replication relative to non-targeting control (z-scores≥1.5) ([Table 2](#t2){ref-type="table"}). Included within this dataset are the hits which resulted in a standard z-score≤−0.5 and z-score≥0.5 compared to non-targeting control.

Data record 2
-------------

The miRNA inhibitor data is available at PubChem under *NCBI PubChem BioAssay* AID 1224851 (Data Citation 2). The top miRNA hits from the mimic screening assays were re-screened in HEp-2 cells, to eliminate false-positive hits. In this case, miRNA inhibitors were tested to determine if they induced a phenotype which correlated with that of the miRNA mimic results. Included within this dataset are the z-scores of all miRNAs inhibitors tested.

Technical Validation
====================

Transfection optimization
-------------------------

To establish a highly efficient miRNA transfection protocol in a high-throughput screening (HTS) fashion, we first investigated four individual DharmaFECT transfection reagents (DF1-4). We identified that DF4 is the most effective in gene silencing for both HEp-2. Further we performed the titration of the concentration of DF4 in both cell lines. In the case with 0.3% DF4 concentration, the GAPDH silencing was achieved \>90%, and cell toxicity was not observed in either microscopy examination or MTT assay.

Cytotoxicity assays
-------------------

Cytotoxicity as a result of miRNA transfection was evaluated by CytoTox-Glo assay (Promega) according to manufacturer instructions. Briefly, HEp-2 cells were reverse transfected with miRNA mimics as described previously^[@b22]^. Forty-eight hours post-transfection cellular toxicity was evaluated. Values were normalized to siTOX control (100% cytotoxic). MiRNAs which elicited greater than 20% toxicity were excluded as is standard practice. In this study, we focused on the miRNA mimics screening, and observed some miR-induced cell death. Toxic miRNAs that lead to cell death including miR-1275, miR-129-3P, miR509, miR-1909, miR323-5P, miR-4265, miR-3661 were excluded from further studies. For the list of hits identified from miRNA mimics screening, we did not observe significant cell death for the corresponding miRNA inhibitors.

Transfection controls
---------------------

A high-quality RNAi screen integrates both excellent experimental design and computational strategies for quality control. A clear distinction between a positive control and a negative reference is paramount. In the current miRNA screen in HEp-2 cell line, a positive control siRNA specifically targeting poliovirus (Poliovirus-specific (VP1 & 3D) and a negative control (non-targeting siRNA) were clearly distinguished from each other in all 96-well plates transfected with siRNAs. siTOX (GE Healthcare Dharmacon TOX Transfection Control, Cat. \# D0015000120) was used to serve as another indicator for transfection efficiency and a mock control used as background normalization.

As part of developing a screening assay with low variation and a strong signal to background ratio we conducted pilot studies to optimize screening conditions. These conditions included optimizing titration of miRNA and siRNAs used to determine the most effective concentrations. Assay responses to negative and positive miRNA and siRNA controls were also evaluated and optimized to determine baseline values and standard deviation value for the calculation of Z-scores. Z-scores were subsequently used to determine hits for further screening. Transfection efficiency was optimized via transfection with miRIDIAN microRNA Mimic housekeeping positive Control \#2 (GAPDH) (Cat. \# CP-001000-02) as well as the inclusion of siTOX transfection control as previously mentioned. MRNA transcription levels were evaluated by qPCR following miRNA transfection and compared to GAPDH control to confirm miRNA mediated mRNA knockdown. Positive controls for poliovirus screening were carefully selected and optimized ([Fig. 6](#f6){ref-type="fig"})^[@b23]^. The culmination of this data suggests high transfection efficiency, low variability and substantial positive control values concluding that our screening procedure is robust.
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![miR-134 inhibits sabin-2 replication in HEp-2c and Caco-2 cells.\
(**a**) Schematic of the experimental design. To evaluate if antiviral effect of miR-134 is cell type-specific, HEp-2c (**b**) and Caco-2 (**c**) cells were reverse-transfected with miR-134-5p mimic or miR mimic non-targeting scrambled negative control (miR-NTC) at a final concentration of 25 nM. After 48 h, the transfected cells were infected with Sabin-2 at MOI of 0.01 for 24 h and the virus titers were determined by plaque assay. Error bars represent s.e.m. and the significant differences are compared with miR-control. Each experiment was performed in quadruplicate and each experiment was repeated twice. The results were reproduced and the data in the figure were representative of 8 plates. \**P*\<0.05, \*\**P*\<0.01.](sdata201723-f1){#f1}

![RAN is a target of miR-134.\
(**a**) Sequence of the putative binding site between miR-134 and 3′UTR of RAN. (**b**) and (**c**) Hep-2c cells were reverse-transfected with miR-134-5p or miR mimic non-targeting scrambled negative control (miR-NTC) at a final concentration of 25 nM. After 48 h, total RNA was isolated from HEp-2c cells, and then miR-134 (**b**) and RAN (**c**) mRNA levels were determined by qRT-PCR. The data were normalized to the 18S rRNA gene and were expressed as fold change relative to mock-transfected cells. The significant differences are compared with miR-control. Each experiment was performed in quadruplicate and each experiment was repeated twice. The results were reproduced and the data in the figure were representative of 8 plates. Error bars represent s.e.m. \**P*\<0.05, \*\*\**P*\<0.001.](sdata201723-f2){#f2}

![Silencing of RAN inhibits PV replication in HEp-2c and Caco-2 cells.\
The cells were reverse-transfected with siRAN or siRNA control at a final concentration of 25 nM. After 48 h, (**a**) total RNA was isolated from HEp-2c cells and RAN mRNA level was determined by qRT-PCR. The data were normalized to the 18S rRNA gene and were expressed as fold change relative to siRNA control. The transfected Hep-2c (**b**) and Caco-2 (**c**) cells were infected with Sabin-2 strain at an MOI of 0.01 for 24 h, and then the virus titers were determined by plaque assay. The significant differences are compared with siRNA control. Error bars represent s.e.m. of quadruplicate. Each experiment was performed in quadruplicate and each experiment was repeated twice. The results were reproduced and the data in the figure were representative of 8 plates. \*\**P*\<0.01, \*\*\**P*\<0.001.](sdata201723-f3){#f3}

![miR-134 targets EV71 replication in RD cells.\
(**a**) Schematic of the experimental design. (**b**) RD cells were reverse-transfected with miR-134-5p or miR mimic non-targeting scrambled negative control (miR-NTC) at final concentration of 25 nM. 48 h later the cells were infected with EV71 at MOI of 0.01 for 24 h and the antiviral effect of miR-134 was determined by plaque assay. Error bars represent s.e.m. of of quadruplicate. Each experiment was performed in quadruplicate and each experiment was repeated twice. The results were reproduced and the data in the figure were representative of 8 plates. The significant differences are compared with miR-control. \*\*\**P*\<0.001.](sdata201723-f4){#f4}

![miRNAs inhibit sabin-2 replication in HEp-2c cells.\
Cells were reverse-transfected with miRNA mimic or miR-control mimic (miR-control) at a final concentration of 25 nM. After 48 h, the transfected cells were infected with Sabin-2 at MOI of 0.01 for 24 h and the virus titers were determined by ESLIA assay.](sdata201723-f5){#f5}

![(a) optimization of transfection using miRIDIAN microRNA mimic housekeeping positive control \#2 (GAPDH) (GE Dharmacon; Cat \# CP-001000-02).\
(**b**) Optimization of positive control (siPol) for virus replication (CDC, provided by Dr Steve Oberste).](sdata201723-f6){#f6}

###### Top anti-PV miRNA hits.

  **miRNA**          **PreCursor Accession**   **Normalize Z-score**     **miRNA**      **PreCursor Accession**   **Normalize Z-score**      **miRNA**      **PreCursor Accession**   **Normalize Z-score**
  ----------------- ------------------------- ----------------------- ---------------- ------------------------- ----------------------- ----------------- ------------------------- -----------------------
  hsa-let-7i\*              MI0000434                 −1.6437           hsa-miR-29b            MI0000105                 −2.0564            hsa-miR-432            MI0003133                 −1.6267
  hsa-miR-1181              MI0006274                 −1.5697           hsa-miR-29c            MI0000735                 −1.8369           hsa-mir-4326          MIMAT0016888                −1.5294
  hsa-miR-1182              MI0006275                 −1.7367           hsa-miR-301b           MI0005568                 −1.7121          hsa-miR-450b-3p          MI0005531                 −1.6297
  hsa-miR-1207-5p           MI0006340                 −1.7136           hsa-miR-30c            MI0000736                 −1.5034          hsa-miR-483-5p           MI0002467                 −1.8311
  hsa-miR-1227              MI0006316                 −1.821           hsa-mir-3118-1        MIMAT0014980                −1.8229          hsa-miR-491-5p           MI0003126                 −1.8349
  hsa-mir-1244-2            MI0015974                 −1.6289           hsa-mir-3123         MIMAT0014985                −1.5285            hsa-miR-497            MI0003138                 −1.5982
  hsa-miR-1250              MI0006385                 −2.173            hsa-mir-3127           MI0014144                 −1.9938          hsa-miR-509-3p           MI0005717                 −2.185
  hsa-miR-1255b             MI0006435                 −1.7509           hsa-mir-3132         MIMAT0014997                −2.0313           hsa-miR-516b            MI0003172                 −1.7892
  hsa-miR-1257              MI0006391                 −2.0261           hsa-mir-3140           MI0014163                 −1.8811           hsa-miR-517b            MI0003165                 −1.5992
  hsa-miR-125b              MI0000446                 −1.7329           hsa-mir-3175         MIMAT0015052                −1.5215          hsa-miR-518a-5p          MI0003170                 −1.5166
  hsa-miR-1274a             MI0006410                 −1.5221           hsa-mir-3186           MI0014229                 −1.7061           hsa-miR-518e            MI0003169                 −1.605
  hsa-miR-1275              MI0006415                 −1.8306           hsa-mir-3190         MIMAT0015073                −1.7578            hsa-miR-522            MI0003177                 −1.8432
  hsa-miR-129-3p            MI0000473                 −1.7159           hsa-mir-3191           MI0014236                 −1.6572            hsa-miR-523            MI0003153                 −1.617
  hsa-miR-129\*             MI0000252                 −1.8363           hsa-mir-3192         MIMAT0015076                −2.0036            hsa-miR-544            MI0003515                 −1.6514
  hsa-miR-1293              MI0006355                 −1.7672           hsa-mir-3194           MI0014239                 −1.721            hsa-miR-545\*           MI0003516                 −1.8565
  hsa-miR-1298              MI0003938                 −1.5262           hsa-miR-320d           MI0008190                 −1.5835          hsa-mir-548aa-1        MIMAT0018447                −1.9087
  hsa-miR-130a              MI0000448                 −1.6326          hsa-miR-323-5p          MI0000807                 −1.8961           hsa-miR-548n            MI0006399                 −1.5612
  hsa-miR-134               MI0000474                 −2.3096          hsa-miR-324-5p          MI0000813                 −1.5969            hsa-miR-555            MI0003561                 −2.0986
  hsa-miR-138               MI0000476                 −2.4403          hsa-miR-330-5p          MI0000803                 −1.8413            hsa-miR-588            MI0003597                 −1.677
  hsa-miR-149\*             MI0000478                 −1.6051          hsa-miR-338-5p          MI0000814                 −1.8383            hsa-miR-597            MI0003609                 −1.5576
  hsa-miR-15b\*             MI0000438                 −1.6419          hsa-miR-342-5p          MI0000805                 −1.898             hsa-miR-608            MI0003621                 −1.744
  hsa-miR-16                MI0000070                 −1.9572          hsa-miR-362-5p          MI0000762                 −1.5916            hsa-miR-609            MI0003622                 −1.7592
  hsa-miR-1908              MI0008329                 −1.5895           hsa-miR-363            MI0000764                 −1.6293            hsa-miR-613            MI0003626                 −1.7465
  hsa-miR-1909              MI0008330                 −1.8725           hsa-mir-3661         MIMAT0018082                −1.7807            hsa-miR-622            MI0003636                 −2.0702
  hsa-miR-1914\*            MI0008335                 −1.6261           hsa-mir-3691           MI0016092                 −1.5575            hsa-miR-624            MI0003638                 −1.6856
  hsa-miR-195               MI0000489                 −1.7648           hsa-miR-381            MI0000789                 −1.6366          hsa-miR-628-5p           MI0003642                 −1.8112
  hsa-miR-197               MI0000239                 −1.8252           hsa-mir-3915         MIMAT0018189                −1.5228            hsa-miR-630            MI0003644                 −1.8071
  hsa-miR-218-2\*           MI0000295                 −1.5057          hsa-miR-411\*           MI0003675                 −1.7965            hsa-miR-663            MI0003672                 −1.6806
  hsa-miR-220c              MI0005536                 −1.6914           hsa-miR-421            MI0003685                 −1.7236            hsa-mir-676            MI0016436                 −1.5983
  hsa-miR-224\*             MI0000301                 −1.8876           hsa-miR-424            MI0001446                 −1.7503           hsa-miR-7-2\*           MI0000264                 −2.0278
  hsa-mir-2278            MIMAT0011778                −1.5577           hsa-mir-4252         MIMAT0016886                −1.5233          hsa-miR-768-3p           MI0005117                 −1.6025
  hsa-mir-2355              MI0015873                 −1.5942           hsa-mir-4255         MIMAT0016885                −1.5652          hsa-miR-769-3p           MI0003834                 −1.977
  hsa-miR-26a               MI0000083                 −1.6853           hsa-mir-4265         MIMAT0016891                −1.6974            hsa-miR-801            MI0005202                 −1.561
  hsa-miR-26b               MI0000084                 −1.7231           hsa-mir-4270         MIMAT0016900                −1.5457            hsa-miR-922            MI0005714                 −1.5015
  hsa-miR-27a\*             MI0000085                 −1.9841           hsa-mir-4292         MIMAT0016919                −1.5023            hsa-miR-924            MI0005716                 −1.5341
  hsa-miR-29a               MI0000087                 −1.8126          hsa-miR-431\*         MIMAT0004757                −1.8885          hsa-miR-92a-1\*          MI0000093                 −1.5144

###### Top pro-PV miRNA hits.

  **miRNA**         **PreCursor Accession**   **Normalized Z-score**      **miRNA**      **PreCursor Accession**   **Normalized Z-score**
  ---------------- ------------------------- ------------------------ ----------------- ------------------------- ------------------------
  hsa-miR-106a             MI0000113                  2.5029            hsa-mir-3622b           MI0016014                  2.8955
  hsa-miR-1183             MI0006276                  2.2776            hsa-mir-3650          MIMAT0018070                 3.0868
  hsa-miR-1256             MI0006390                  2.2043           hsa-miR-371-3p         MIMAT0000723                 3.0328
  hsa-mir-1270-2           MI0006407                  1.8131           hsa-mir-3913-1           MI0016417                  1.8771
  hsa-miR-1290             MI0006352                  2.1255             hsa-miR-411            MI0003675                  1.6903
  hsa-miR-148b             MI0000811                  2.1563             hsa-miR-429          MIMAT0001536                 2.3367
  hsa-miR-182              MI0000272                  1.813             hsa-mir-4300          MIMAT0016853                 2.2905
  hsa-miR-1825             MI0008193                  1.6288            hsa-mir-4311          MIMAT0016863                 1.8049
  hsa-miR-185\*            MI0000482                  2.5167             hsa-miR-488            MI0003123                  1.7722
  hsa-miR-190b             MI0005545                  1.5325           hsa-miR-512-3p           MI0003140                  2.4828
  hsa-miR-1977             MI0009987                  2.8377           hsa-miR-513a-5p          MI0003191                  1.6767
  hsa-miR-1978             MI0009988                  2.033            hsa-miR-519c-3p          MI0003148                  1.5004
  hsa-mir-2115\*         MIMAT0011159                 2.2428            hsa-miR-519d            MI0003162                  1.789
  hsa-miR-216a             MI0000292                  1.5712           hsa-miR-520c-3p          MI0003158                  2.1928
  hsa-miR-22               MI0000078                  1.6283           hsa-miR-520d-3p          MI0003164                  2.3981
  hsa-miR-221\*            MI0000298                  2.2304            hsa-miR-520e            MI0003143                  1.7425
  hsa-mir-3155           MIMAT0015029                 1.7369           hsa-miR-526b\*           MI0003150                  2.2129
  hsa-mir-3160-1           MI0014189                  2.0883             hsa-miR-559            MI0003565                  1.8168
  hsa-mir-3162             MI0014192                  2.7709             hsa-miR-571            MI0003578                  1.9588
  hsa-mir-3187             MI0014231                  2.0815           hsa-miR-576-3p           MI0003583                  2.4894
  hsa-mir-3605             MI0015995                  1.7167             hsa-miR-589            MI0003599                  2.0177
  hsa-miR-361-5p           MI0000760                  2.295              hsa-miR-598            MI0003610                  1.5474
  hsa-mir-3620             MI0016011                  2.5204              hsa-miR-9             MI0000466                  2.1298
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